Nuclear Medicine Therapy

  ARE YOU SUFFERING FROM HCC? (We are recruiting subjects for a clinical trial in the use of GPC-3 based PET-CT scan in patients of Hepatocellular Carcinoma). Backgroung: Glypican-3 (GPC3) is an oncofetal glycoprotein attached to the cell membrane. The expression of GPC3 is seen in various tumors, most notably in hepatocellular carcinomas(HCCs). Since GPC3 is not expressed in normal adult human tissue. GPC3 is considered an attractive target for tumor-directed diagnostics and therapy. If you are more than 18 years of age and suffering from a suspected hepatocellular carcinoma you may be eligible for this trial. Read more at https://nuclearmedicinetherapy.in/blog/hepato-cellular-carcinoma-hcc-clinical-trial Original Source: https://nuclearmedicinetherapy.in

  The incidence of Hepatocellular Carcinoma or HCC has been increasing over the past several years and several studies have projected that the incidence of HCC will continue to rise in the coming years. Transarterial Chemoembolisation or TACE has been the initial treatment modality for HCC and has a huge body of evidence from several studies and clinical trials. Therefore, for long TACE has been a preferred treatment algorithm for unresectable HCC. However, as the experience of  Transarterial Radioembolisation or TARE  has evolved, it is playing an increasingly important role in the treatment of unrespectable HCC. Studies and trials have shown that TARE has many potential advantages over TACE and there is now substantial evidence to favor TARE over TACE. The many potential advantages of TARE when compared with TACE are as below: · Several studies have shown a statistically significant overall survival advantage with TARE as compared to TACE. · TARE has better health-relat...